Predictive value of serum inflammatory markers in immunotherapy of non-small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 177-180, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-930061
ABSTRACT
Immune checkpoint inhibitors (ICIs) can not only prolong the survival time of patients with non-small cell lung cancer (NSCLC) in a short time, but also achieve a lasting response to the tumor. However, there has been significant heterogeneity in the efficacy of ICIs among patients with different types of NSCLC, and there has been still a lack of universal biomarkers to predict the benefit of ICIs treatment. Inflammation has played a definite role in the occurrence and development of tumors, and a variety of inflammatory markers in serum also have become clinical indicators reflecting immune status, such as lactate dehydrogenase, C-reactive protein, serum neutrophils, lymphocytes, platelets and other indicators. These inflammatory markers are easy to obtain and are associated with the prognosis of a variety of solid tumors.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
Journal of International Oncology
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS